**This letter is for you to adapt for your patient(s). Please ensure that you customise the text highlighted in yellow so that the information is appropriate. Please also ensure that once you have made your amendments, any important information isn’t split across two pages, or that an instruction to continue on to a second page is added.**

Insert practice header or print to practice headed paper, or type address details below.

[Practice name]

[Address]

[Tel]

[Fax]

[Email]

[Date]

[Title\_Initial\_Surname]

[Patient Address Block]

Dear [Title] [Surname],

This practice constantly reviews repeat prescriptions to make sure that our patients get the most effective treatment, which in turn provides good value for the NHS without affecting their quality of care.

We are currently reviewing the medicines we use to treat ulcerative colitis and Crohn’s disease, particularly mesalazine modified release (MR) tablets.

We have decided to use Octasa MR as our preferred brand of mesalazine modified release tablets. Octasa MR is as effective as the mesalazine you are taking now and is more cost effective. It is the same strength and is taken at the same dose. This choice is supported by NHS Dorset and supersedes any prescription you may have previously received.

We do not expect you to experience any change in symptom control or any side-effects as a result of this change but please contact your GP/Nurse/Pharmacist if you have any questions or concerns.

|  |  |
| --- | --- |
| **GP/Nurse/Pharmacist** [delete as applicable] | [Add number] |

Yours sincerely

Dr [insert name] and partners

More information and support is available from: <https://www.crohnsandcolitis.org.uk/>